Form 4: Kiniksa Pharmaceuticals CFO Reports Stock Option Exercises and Sales

Mark Ragosa, CFO of Kiniksa Pharmaceuticals, reports exercising stock options and selling Class A Ordinary Shares under a pre-arranged 10b5-1 trading plan.

Summary

• Mark Ragosa, the Chief Financial Officer of Kiniksa Pharmaceuticals International, plc, filed a Form 4 detailing changes in beneficial ownership.
• The report covers transactions that occurred between April 29, 2025, and May 1, 2025.
• Ragosa exercised stock options to acquire Class A Ordinary Shares at prices of $15.52, $15.50, $16.90, $17.92 and $17.76.
• He then sold portions of these shares at a weighted average price of $25.61 on April 29, 2025, and at $26.95 and $27.80 on April 30 and May 1, 2025, respectively.
• These transactions were executed under a 10b5-1 plan established on September 3, 2024.
• Following these transactions, Ragosa directly owns 27,009 Class A Ordinary Shares and holds options for 31,380 shares.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it is a routine disclosure of stock option exercises and sales by the CFO. The transactions are conducted under a pre-arranged 10b5-1 plan, suggesting they are not based on any specific inside information.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency into the transactions of company insiders, allowing investors to monitor potential alignment or misalignment of interests between management and shareholders.

Stakeholder Impact

• The transactions may have a minor impact on shareholders by increasing the number of shares available in the market.
• The CFO's actions could be interpreted as a sign of confidence or lack thereof, although the 10b5-1 plan mitigates this interpretation.

Key Dates

Keywords

Form 4, Kiniksa Pharmaceuticals, Mark Ragosa, CFO, Stock Options, Class A Ordinary Shares, Beneficial Ownership, 10b5-1 Plan, SEC